ATAI and CMPS will both underperform the XBI (SPDR S&P Biotech ETF) on total return from June 6 to September 30, 2026, absent a positive Phase 2b or Phase 3 data readout

ATAI and Compass are pure psychedelic research companies with no drugs sold yet — they only make money if their clinical trials succeed. The XBI (SPDR S&P Biotech ETF) tracks the entire biotech sector, which includes many companies that already sell drugs and generate revenue. After the hype around psychedelics cooled (especially after the MDMA regulatory setback), these two stocks will likely fall in value relative to the broader biotech industry unless they announce positive results from late-stage clinical trials.

Both companies are pre-revenue clinical-stage psychedelic biotechs in a sector facing post-hype multiple compression. XBI reflects diversified biotech with revenue-generating components. The conditional qualifier (absent positive Phase 2b/3 readout) makes this falsifiable and honest about the key invalidating scenario. Sector sentiment is negative following MDMA regulatory setback. Without a binary catalyst, mean reversion toward cash-burn discount is the base case. Resolves via Bloomberg total return comparison on September 30, 2026.